Exploring different exercise types for treating Non-Alcoholic Fatty Liver Disease
Investigation of Effectiveness of Different Exercise Types, and Their Therapeutic Effect Mechanisms and the Roles of Motivational Interview in the Treatment of Non-Alcoholic Fatty Liver Disease
This study is testing different types of exercise, like high-intensity workouts and strength training, to see how they can help people with Non-Alcoholic Fatty Liver Disease feel better over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 144 (estimated) |
| Ages | 25 Years to 50 Years |
| Sex | All |
| Sponsor | Yeditepe University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Istanbul, Ataşehir) |
| Trial ID | NCT06257732 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of various exercise modalities, including high-intensity interval training (HIIT), resistance training, and FATmax exercises, in treating Non-Alcoholic Fatty Liver Disease (NAFLD) over a 12-week period. Participants will be randomly assigned to different exercise groups and will also receive motivational interviewing to support lifestyle changes. The study aims to assess how these interventions impact myokine levels related to lipid metabolism and overall treatment outcomes for NAFLD. A control group receiving standard care will be included for comparison.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 25 to 50 diagnosed with Non-Alcoholic Fatty Liver Disease who use a smartphone.
Not a fit: Patients with advanced liver disease, significant comorbidities, or those on specific medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new exercise-based treatment options for patients with NAFLD, potentially improving liver health and metabolic outcomes.
How similar studies have performed: Previous studies have shown promising results with exercise interventions for NAFLD, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have received a diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) * Age between 25 and 50 years old * Use of smartphone * Fall into category A or B according to the American Heart Association Risk Assessment Criteria Exclusion Criteria: * Viral hepatitis * Excessive alcohol consumption (more than 30 grams per day for men and more than 20 grams per day for women) * Use of specific medications: amiodarone, corticosteroids, methotrexate, tamoxifen, synthetic estrogen, valproic acid, intravenous tetracycline, and highly active antiretroviral drugs * Presence of accompanying chronic diseases such as Wilson's disease, hemochromatosis, and celiac disease * Liver storage diseases * Cancer * Cirrhosis * Advanced changes in liver ultrasonography evaluations, such as fibrosis * Presence of other chronic diseases (kidney failure, heart failure, atherosclerotic heart disease, hypertension, arrhythmia disorders) * BMI greater than 40 kg/m² * History of surgery or trauma in the last 6 months * Orthopedic and/or neurological impairment * Health problems that may hinder participation in the exercise program * Regular and continuous participation in sports or exercise at least 3 times a week for the past 3 years * Family history of coronary artery disease (coronary artery disease before the age of 45 in male first-degree relatives and other male relatives, or before the age of 65 in female first-degree relatives and other female relatives) * Presence of specific symptoms during medical history or physical examination: chest pain radiating to the neck, jaw, or arm, shortness of breath during rest or physical activity, dizziness, fainting, orthopnea or paroxysmal nocturnal dyspnea, ankle edema, palpitations or tachycardia, intermittent claudication, heart murmur, unexplained excessive fatigue * Fall into category C or D according to the American Heart Association Risk Assessment Criteria
Where this trial is running
Istanbul, Ataşehir
- Yeditepe University — Istanbul, Ataşehir, Turkey (Recruiting)
Study contacts
- Study coordinator: Mehtap Kaçar, MD, PhD, Prof
- Email: mehtap.kacar@yeditepe.edu.tr
- Phone: +90 (216) 578 00 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.